Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

Abstract Objectives The SWORD trial is the first multicenter, single arm, phase II study assessing the safety and efficacy of a PD-1 inhibitor (Sintilimab), stereotactic body radiotherapy (SBRT) and granulocyte–macrophage colony stimulating factor (GM-CSF) in advanced non-small cell lung cancer (NSC...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jianjiao Ni, Yue Zhou, Lin Wu, Xinghao Ai, Xiaorong Dong, Qian Chu, Chengbo Han, Xiaofei Wang, Zhengfei Zhu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-09-01
coleção:	Radiation Oncology
Assuntos:	Sintilimab Stereotactic body radiotherapy (SBRT) Granulocyte–macrophage colony stimulating factor (GM-CSF) Non-small cell lung cancer (NSCLC) Treatment-related adverse event (TRAE)
Acesso em linha:	https://doi.org/10.1186/s13014-021-01905-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!